Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...
KeyBanc Capital Markets maintained its Overweight rating for Recursion following the FDA approval. In addition, Recursion announced a $30 million deal with Genentech and plans for a $200 million ...
First program to combine Recursion's end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results